Completed OBSERVATIONAL NCT01376115

Drug Use Investigation for ARRANON G (Nelarabine) Injection 250mg

Sponsor: Novartis Pharmaceuticals

Conditions Cancer

Interventions Nelarabine

Updated 9 times since 2017 Last updated: Oct 30, 2017 Started: Jan 18, 2008 Primary completion: Oct 24, 2017 Completion: Oct 24, 2017

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This observational or N/A phase trial investigates Cancer and is currently completed. Novartis Pharmaceuticals leads this study, which shows 9 recorded versions since 2008 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

9 versions recorded

Sep 2024 — Present [monthly]

Completed
Jul 2024 — Sep 2024 [monthly]

Completed
Jan 2021 — Jul 2024 [monthly]

Completed
Jun 2018 — Jan 2021 [monthly]

Completed
Apr 2018 — Jun 2018 [monthly]

Completed

Phase: NA → None

▶ Show 4 earlier versions

Nov 2017 — Apr 2018 [monthly]

Completed NA

Status: Recruiting → Completed
Jun 2017 — Nov 2017 [monthly]

Recruiting NA
May 2017 — Jun 2017 [monthly]

Recruiting NA

Status: Active Not Recruiting → Recruiting
Jan 2017 — May 2017 [monthly]

Active Not Recruiting NA

First recorded

Jan 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Novartis Pharmaceuticals

Data source: Novartis

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Tsukuba, Japan